Interleukin 1 beta synergises with interleukin 2 in the outgrowth of autologous tumour-reactive CD8+ effectors.

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Interleukin 1 beta synergises with interleukin 2 in the outgrowth of autologous tumour-reactive CD8+ effectors.

Br J Cancer. 1994 Oct;70(4):625-30. Unique Identifier : AIDSLINE MED/95001345
Baxevanis CN; Dedoussis GV; Gritzapis AD; Stathopoulos GP; Papamichail M; Department of Immunology, Hellenic Anticancer Institute, Athens,; Greece.

Abstract: Using peritoneal fluid or pleural effusion obtained from 20 patients with lung, ovarian or metastatic breast cancer, we separated tumour cells from malignant effusion-associated mononuclear cells (MEMNCs) using discontinuous Ficoll-Hypaque density gradients. CD3+ T lymphocytes represented the main population of MEMNCs. The mean +/- s.d. CD4/CD8 ratio of MEMNC suspensions was 1.18 +/- 0.40. MEMNCs proliferated and expanded in vitro with human interleukin 2 (IL-2) either as CD3+ CD8+ cells or as CD3+ CD4+ cells or as mixed populations of CD8+ and CD4+ cells. Preferential cytolytic activity against autologous tumour cells was demonstrated in IL-2-activated MEMNC cultures with excess CD3+ CD8+ cells. In contrast, effectors derived from IL-2-activated cultures with excess CD3+ CD4+ cells lysed both autologous and allogeneic tumour target cells. The addition on day 0 of interleukin 1 beta (IL-1 beta) to MEMNCs cultured in the presence of IL-2 was effective in promoting the growth of CD3+ CD8+ cells and augmenting the cytotoxicity against autologous tumour. Simultaneously, the production of gamma-interferon (IFN-gamma) was increased in these cultures. This is the first report suggesting that IL-1 beta synergises with IL-2 to induce autologous tumour-specific CD8+ cytotoxic T lymphocytes (CTLs) within the MEMNC population. Selective enrichment in T-cell subsets by IL-1 beta may be useful in cellular adoptive immunotherapy using cells isolated from malignant effusions.

Keywords: Adult Aged Ascitic Fluid/CYTOLOGY Breast Neoplasms/IMMUNOLOGY/PATHOLOGY Cell Division/DRUG EFFECTS Cells, Cultured Comparative Study CD8-Positive T-Lymphocytes/DRUG EFFECTS/IMMUNOLOGY/*METABOLISM Drug Synergism Female Human Interferon Type II/METABOLISM Interleukin-1/*PHARMACOLOGY Interleukin-2/*PHARMACOLOGY Lung Neoplasms/IMMUNOLOGY/PATHOLOGY Middle Age Ovarian Neoplasms/IMMUNOLOGY/PATHOLOGY Pleural Effusion, Malignant/CYTOLOGY T-Lymphocytes, Cytotoxic/*DRUG EFFECTS/IMMUNOLOGY/METABOLISM JOURNAL ARTICLE
950130
M9510826

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .